Sunday, March 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Identifying and Optimizing Chemical Threat Countermeasures

by Global Biodefense Staff
March 14, 2016
NIH CounterACT Chemical Countermeasure Program

The National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program has released two new funding opportunities to support identification and optimization of therapeutics to treat exposures to chemical warfare agents and toxic industrial chemicals.

The civilian chemical threat spectrum includes chemical warfare agents (e.g., sarin), toxic industrial chemicals (e.g., cyanide), pesticides (e.g., parathion), and other chemicals.

NIH CounterACT cooperative agreement projects will support studies to generate the tools, efficacy in an appropriate animal model, and safety and pharmacology data necessary to transition the proposed therapeutics to advanced drug development, regulatory approval, and licensure.

Identification of Therapeutic Lead Compounds

PAR-16-129

Supports research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. Includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data.

Optimization of Therapeutic Lead Compounds

PAR-16-128

The scope of research supported includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans.  It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies. A previously identified lead compound is required to be eligible for this funding opportunity.

Funding for this effort will only support the development of lead compounds that can be used to reduce mortality or serious morbidity during a chemical emergency. The primary focus is on post-exposure efficacy; compounds that are only effective if administered prior to the chemical insult (prophylaxis efficacy) will be of lowest priority.

Applicants are encouraged to collaborate with laboratories that are already certified and legally authorized to work with restricted chemical agents, such as the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and certain contract research organizations, when applicable.

Tags: Animal ModelsNIHRequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC